Video

VIDEO: Therapies for sarcoma show promise, but more research needed

The use of NY-ESO-1-specific T cells for the treatment of synovial sarcoma and myxoid/round-cell liposarcoma demonstrated evidence of clinical activity and disease regression, according to research Seth M. Pollack, MD, of Seattle Cancer Care Alliance and Fred Hutchinson Cancer Research Center, presented at the ASCO Annual Meeting.

Pollack says that there’s exciting research surrounding T cell therapies for sarcoma, but “there’s a lot more that needs to be done.”

Pollack – who was a part of an education session that focused on the future of immunotherapy in sarcoma – also discusses research presented by Sandra P. D'Angelo, MD, of Memorial Sloan Kettering Cancer Center, which highlighted that the use of pembrolizumab (Keytruda, Merck) demonstrated a response in patients with pleomorphic and synovial sarcoma.

“I think this suggests that there is definitely a potential for activity with these drugs but we need to be combining the drugs with other agents in order to get more consistent and long-lasting complete activity,” he said.

The use of NY-ESO-1-specific T cells for the treatment of synovial sarcoma and myxoid/round-cell liposarcoma demonstrated evidence of clinical activity and disease regression, according to research Seth M. Pollack, MD, of Seattle Cancer Care Alliance and Fred Hutchinson Cancer Research Center, presented at the ASCO Annual Meeting.

Pollack says that there’s exciting research surrounding T cell therapies for sarcoma, but “there’s a lot more that needs to be done.”

Pollack – who was a part of an education session that focused on the future of immunotherapy in sarcoma – also discusses research presented by Sandra P. D'Angelo, MD, of Memorial Sloan Kettering Cancer Center, which highlighted that the use of pembrolizumab (Keytruda, Merck) demonstrated a response in patients with pleomorphic and synovial sarcoma.

“I think this suggests that there is definitely a potential for activity with these drugs but we need to be combining the drugs with other agents in order to get more consistent and long-lasting complete activity,” he said.

    See more from ASCO Annual Meeting